Waters Corporation $WAT Shares Sold by Eos Management L.P.

Eos Management L.P. decreased its holdings in Waters Corporation (NYSE:WAT - Free Report) by 16.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,699 shares of the medical instruments supplier's stock after selling 2,465 shares during the quarter. Waters comprises about 1.9% of Eos Management L.P.'s portfolio, making the stock its 17th biggest position. Eos Management L.P.'s holdings in Waters were worth $4,432,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in WAT. Olde Wealth Management LLC acquired a new stake in shares of Waters in the 1st quarter worth $25,000. Zions Bancorporation National Association UT purchased a new position in Waters in the 1st quarter worth $28,000. IFP Advisors Inc raised its stake in Waters by 118.9% in the 1st quarter. IFP Advisors Inc now owns 81 shares of the medical instruments supplier's stock worth $30,000 after acquiring an additional 44 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Waters in the 1st quarter worth $41,000. Finally, Steph & Co. purchased a new position in Waters in the 2nd quarter worth $73,000. Institutional investors and hedge funds own 94.01% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. UBS Group restated a "neutral" rating on shares of Waters in a research note on Tuesday, July 15th. Scotiabank restated a "sector outperform" rating and issued a $465.00 target price on shares of Waters in a research note on Friday, July 11th. Robert W. Baird reduced their target price on Waters from $374.00 to $352.00 and set an "outperform" rating for the company in a research note on Wednesday, July 16th. Wall Street Zen lowered Waters from a "buy" rating to a "hold" rating in a research note on Saturday, July 26th. Finally, Redburn Partners set a $390.00 price objective on Waters in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $376.80.

Waters Stock Performance

Shares of NYSE WAT opened at $335.58 on Monday. The company's fifty day moving average price is $305.36 and its 200 day moving average price is $322.73. Waters Corporation has a 1 year low of $275.05 and a 1 year high of $423.56. The company has a market capitalization of $19.97 billion, a PE ratio of 30.26, a price-to-earnings-growth ratio of 3.12 and a beta of 1.04. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.22 and a current ratio of 1.75.

Waters (NYSE:WAT - Get Free Report) last issued its quarterly earnings results on Thursday, May 19th. The medical instruments supplier reported $2.29 earnings per share (EPS) for the quarter. The company had revenue of $608.55 million for the quarter. Waters had a return on equity of 38.60% and a net margin of 21.71%. On average, research analysts predict that Waters Corporation will post 12.86 earnings per share for the current year.

About Waters

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.